The beginnings of the Department of Dermatology at The Mount Sinai Hospital can be traced to a Clinic for Skin and Venereal Diseases founded in 1891 in the Outpatient Department. In the early part of the 20th century, the skin clinics of The Mount Sinai Hospital were widely recognized and respected for their outstanding work and breakthroughs in treatment. Dermatologists and physicians of other specialties came from all parts of the country to visit Mount Sinai's Dermatology Department and learn from our findings.
In 1929, our Department joined forces with the Division of Dermatopathology. This partnership resulted in several major breakthroughs in therapies used in the treatment of skin diseases.
In 1949, our residency program was created. Since then we've graduated many highly respected dermatologists. Our research placed the necessary spotlight on skin conditions such as industrial dermatoses, insect-bite reactions, melanin, and mycology.
Through the 1970's, Mount Sinai's Dermatology Department continued to expand the dermatologic surgery clinic. We have been at the forefront of cosmetic procedures since then, and physicians from around the world come to The Mount Sinai Hospital to train in a wide array of cosmetic procedures on a regular basis. We were one of the first departments in the nation to receive accreditation for a procedural dermatology fellowship. We have also built one of the largest phototherapy units in the nation, where we treat many patients with psoriasis, vitiligo, cutaneous T cell lymphoma, eczema, and other disorders.
Our Current Goals
Our Department is recognized around the world for developing many of the therapies used for psoriasis. Our Psoriasis Program also features an infusion unit for the administration of intravenous therapies such as infliximab. Many of the guidelines for using systemic agents, including methotrexate, cyclosporine, acitretin, and biologic therapies for this disorder, were developed at Mount Sinai.
In addition, we hold the patent for use of the excimer laser for the treatment of vitiligo. We have also been at the forefront of the development of new therapies such as implantable afamelanotide for vitiligo. In our clinical trials, we are testing other biologic therapies for this condition.
We have developed a center of excellence in atopic dermatitis and other eczematous disorders. Patch testing for occupational dermatoses and contact dermatitis are performed in our Eczema Center. We are among few hospitals worldwide which now participate in novel therapeutic developments in eczema and are able to offer them to our patients.
In our laboratory for inflammatory skin diseases, we have defined candidate cytokines, which can be targeted by novel drugs to improve eczema. Our clinical trials unit is testing a number of these promising therapeutic targets for the treatment of eczema. We hope these treatments will improve the lives of eczema patients around the world.
In 2013, Mount Sinai merged with the Continuum Health Partners, a group of respected hospitals and ambulatory practices spread across New York City. This created the Mount Sinai Health System, an integrated health system of seven member hospital campuses affiliated with a single medical school, the Icahn School of Medicine at Mount Sinai. With this merger, the Department of Dermatology at Mount Sinai became the largest in the country with over 250 faculty members covering broad areas of research, clinical trials, and state-of-the-art patient care.
Mount Sinai Dermatology
5 East 98th Street, 5th Floor
New York, NY 10029
To start receiving news and information from the Department of Dermatology, send your name and mailing address to firstname.lastname@example.org